LCP-AtorFen

DRUG2 trials

Sponsors

Veloxis Pharmaceuticals

Conditions

Dyslipidemia

Phase 2

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

CompletedNCT00504829

Veloxis PharmaceuticalsDyslipidemia

Start: 2007-07-31End: 2008-07-31Updated: 2020-02-17

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

CompletedNCT00664859

Veloxis PharmaceuticalsDyslipidemia

Start: 2007-10-31End: 2009-02-28Updated: 2020-03-24